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SUMMARY
Background
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent
cause of liver disease in Western countries. The development of non-
alcoholic steatohepatitis (NASH) and ﬁbrosis identiﬁes an at-risk group
with increased risk of cardiovascular and liver-related deaths. The identiﬁ-
cation and management of this at-risk group remains a clinical challenge.
Aim
To perform a systematic review of the established and emerging strategies
for the diagnosis and staging of NAFLD.
Methods
Relevant research and review articles were identiﬁed by searching PubMed,
MEDLINE and EMBASE.
Results
There has been a substantial development of non-invasive risk scores, bio-
marker panels and radiological modalities to identify at-risk patients with
NAFLD without recourse to liver biopsy on a routine basis. These modali-
ties and algorithms have improved signiﬁcantly in their diagnosis and stag-
ing of ﬁbrosis and NASH in patients with NAFLD, and will likely impact
on the number of patients undergoing liver biopsy.
Conclusions
Staging for NAFLD can now be performed by a combination of radiological
and laboratory techniques, greatly reducing the requirement for invasive
liver biopsy.
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Alimentary Pharmacology and TherapeuticsINTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) encompasses
a spectrum of disease ranging from simple steatosis, to
inﬂammatory steatohepatitis (NASH) with increasing lev-
els of ﬁbrosis and ultimately cirrhosis. NAFLD is closely
associated with obesity and insulin resistance, and is now
recognised to represent the hepatic manifestation of the
metabolic syndrome. Since the term NASH was ﬁrst
coined by Ludwig et al. in 1980,
1 the prevalence of
NAFLD has risen rapidly in parallel with the dramatic
rise in population levels of obesity and diabetes,
2 result-
ing in NAFLD now representing the most common
cause of liver disease in the Western world.
3
Despite recent advances in elucidating the complex met-
abolic and inﬂammatory pathways involved in NAFLD, the
pathogenesis of steatosis and progression to steatohepatitis
and ﬁbrosis⁄cirrhosis is not yet fully understood.
4, 5 While
steatosis alone appears to be associated with a relatively
benign prognosis,
6 factors known to be involved in progres-
sion to more advanced and clinically relevant disease
include inﬂammatory cytokines⁄adipokines, mitochondrial
dysfunction and oxidative stress.
7 Insulin resistance causes
impaired suppression of adipose tissue lipolysis, leading to
increased efﬂux of free fatty acids (FFA) from adipose tissue
to the liver.
8 Hyperinsulinaemia also promotes hepatic de
novo lipogenesis, which is markedly increased in NAFLD
patients compared with normal individuals.
9 It is now
recognised that FFA promote insulin resistance, inﬂamma-
tion and oxidative stress,
10, 11 and thus rather than being
harmful, hepatic triglyceride accumulation may actually be
protective by preventing the harmful effects of FFA.
12 The
important role of oxidative stress mechanisms, pro-inﬂam-
matory cytokines such as TNFalpha and interleukin 6, and
adipokines such as leptin (proinﬂammatory and pro-ﬁbro-
tic), and adiponectin (anti-inﬂammatory and insulin-sensi-
tising), in promoting NASH are also becoming increasingly
delineated.
5 However, evidence that only a minority of
patients with NAFLD progress to more advanced stages of
NASH suggests that disease progression is likely to depend
on a complex interplay between such factors and underlying
genetic predisposition.
4, 7
The causes, epidemiology and natural history of NA-
FLD will be covered brieﬂy, before discussing the estab-
lished and emerging means of assessing and staging
patients with NAFLD.
Causes of NAFLD
In the great majority of cases, NAFLD arises in associa-
tion with one or more features of the metabolic syn-
drome, namely insulin resistance, glucose intolerance or
diabetes, central obesity, dyslipidaemia and hyperten-
sion.
13–15 However, after exclusion of a history of signiﬁ-
cant alcohol intake, which is conventionally <20 g⁄day,
16
other causes of steatosis which should be considered
include nutritional causes, e.g. rapid weight loss and total
parenteral nutrition, rare metabolic disorders and drug-
induced steatosis. Commonly implicated agents include
glucocorticoids, amiodarone, synthetic oestrogens and
highly active antiretroviral drugs (HAART).
16–18 Steatosis
is also frequently associated with hepatitis C, particularly
genotype 3, and endocrine disorders such as polycystic
ovary syndrome (PCOS),
19, 20 hypopituitarism
21 and
hypothyroidism.
22
Epidemiology
The prevalence of NAFLD is estimated to be between
20% and 30% in Western adults,
23, 24 rising to 90% in
the morbidly obese.
25 NASH, the more advanced and
clinically important form of NAFLD, is less common,
with an estimated prevalence of 2–3% in the general
population
16 and 37% in the morbidly obese.
25 Of con-
cern, NAFLD now affects 3% of the general paediatric
population, rising to 53% in obese children,
26, 27 with
considerable implications for future disease burden. Stea-
tosis was present in 70% of a large unselected cohort of
patients with type 2 diabetes.
28
Non-alcoholic fatty liver disease affects all ethnic
groups, although prevalence appears to be higher in His-
panic and European Americans compared with African-
Americans. This difference remains after controlling for
insulin resistance and obesity
23, 29 and may be related to
ethnic differences in lipid metabolism.
23, 30
Natural history
Patients with a diagnosis of NAFLD have been shown
across several studies to have a worse outcome when
compared with an age and sex-matched general popula-
tion.
31 Of note, the excess mortality in this group is
attributable to both cardiovascular and liver-related
causes.
32, 33 Since the description in 1999 of the prognos-
tic relevance of different histological types of NAFLD,
34
several subsequent studies have demonstrated that the
presence of just simple steatosis, with no inﬂammation
or ﬁbrosis, is associated with a similar overall and liver-
related mortality to that of an age and gender matched
general population. This reinforces the need to stratify
patients with NAFLD into simple steatosis or more
advanced disease. More advanced disease can be deﬁned
as advancing levels of ﬁbrosis and⁄or the presence⁄level
J J. . K K. . D Do ow wm ma an n e et t a al l. .
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tion is pertinent as cohort studies thus far have only
identiﬁed advanced ﬁbrosis, and not inﬂammation, as a
predictor of worse clinical outcome.
32 This may be a type
2 error reﬂecting small sample sizes, or it may be attrib-
uted to additional factors such as PNPLA3 polymor-
phisms
35 regulating the development of ﬁbrosis.
METHODS
A systematic literature search was performed to identify
studies assessing methods for the diagnosis and staging
of NAFLD⁄NASH. Relevant articles were identiﬁed by
searching the PubMed database, MEDLINE and
EMBASE, limited to articles published in the English
language but not date-restricted. Search terms included
fatty liver, NAFLD, NASH, steatosis, AND biomarkers,
non-invasive, diagnosis, assessment, staging. Additional
searches were also made for each of the individual
methods described, e.g. NAFLD ﬁbrosis score, transient
elastography, Fibroscan, Fibrotest etc. Selected articles
referenced in these publications were also examined.
Inclusion criteria
Studies were included if:
(i) they were meta-analyses, systematic reviews or pri-
mary studies of one or more relevant diagnostic⁄staging
tool;
(ii) they included at least 30 subjects, to reduce the
risk of including underpowered studies;
(iii) liver biopsy was used as the reference standard;
(iv) the diagnosis of NAFLD had been established
with exclusion of other causes of liver disease.
Exclusion criteria
Studies were excluded if:
(i) publications were not in English;
(ii) data on disease stage e.g. ﬁbrosis stage, was not
identiﬁable;
(iii) they were only presented in abstract form.
Using the search strategy described above, approxi-
mately 150 articles were considered. Following review, 68
articles met the selection criteria and were included in
the analyses.
Data extraction
JD performed the data extraction, which was then
checked by the remaining authors (PN and JT).
NAFLD: MAKING THE DIAGNOSIS
The diagnosis of NAFLD should be strongly suspected
in the presence of features such as obesity, diabetes
and obstructive sleep apnoea (OSA); however, other
causes should always be considered before attributing
abnormal liver function tests (LFTs) to NAFLD alone
(Figure 1). Alternative diagnoses which should be
excluded by history and serological testing include the
viral hepatitides, excess alcohol consumption, haemo-
chromatosis, autoimmune liver disease, alpha-1 anti-
trypsin deﬁciency, Wilson’s disease and drug-induced
liver dysfunction.
The majority of patients with NAFLD are asymptom-
atic and the diagnosis suspected after ﬁnding elevated
transaminases on routine testing. Hepatic steatosis is also
a frequent incidental ﬁnding on ultrasound scan (US)
performed for other reasons such as suspected gallstone
Confirm diagnosis
Repeat LFTs to check if still abnormal
ALT men >30 women >19
LFTs still abnormal
Liver screen and USS
Hep B and C serology,ferritin/transferrin saturation,
liver autoantibodies (AMA, ASMA, ANA),
alpha-1-anti trypsin levels, ceruloplasmin if <40.
Liver screen positive Liver screen negative Liver screen negative
Manage as per condition Normal USS Echobright liver on USS
NAFLD/NASH ?Cause
? Mild Steatosis
Figure 1 | Making the diagnosis
of NAFLD.
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quadrant discomfort and fatigue, although the latter may
also be caused by OSA which is frequently observed in
the typically obese population with NAFLD. Hepatomeg-
aly is the most common clinical ﬁnding, with signs of
chronic liver disease rarely present in the absence of
cirrhosis. A recent study reported the novel ﬁnding that
increased dorsocervical lipohypertrophy was the anthro-
pometric parameter most strongly associated with
severity of steatohepatitis.
36
Although NAFLD is often diagnosed after the ﬁnding
of mildly abnormal LFTs, more than two thirds of
patients have normal aminotransferase levels at any
given time
37 and the entire histological spectrum of
NAFLD can be observed in patients with normal alanine
aminotransferase (ALT) values.
38, 39 ALT is usually
greater than aspartate aminotransferase (AST), and rarely
more than three times the upper limit of normal. An
AST:ALT ratio greater than 1.0 suggests the presence of
more advanced disease.
40 Alkaline phosphatase can be
slightly elevated but is rarely the only liver function test
abnormality.
41 Gamma-glutamyltransferase (GGT) is
frequently elevated and may also be a marker of
increased mortality.
42, 43 Low albumin and hyperbilirubi-
naemia indicate advanced liver disease and are not other-
wise features of NAFLD.
44 Iron studies may show an
elevated ferritin in up to 50% of patients and elevated
transferrin saturation in approximately 10%.
40 However,
such ﬁndings do not appear to correlate with elevated
hepatic iron concentration, and the role of hepatic iron
in the pathogenesis of NASH remains unclear.
45
The Fatty Liver Index (FLI) was developed as a simple
algorithm to predict fatty liver on USS in the general pop-
ulation.
46 The FLI uses four variables of BMI, waist cir-
cumference, GGT and serum triglyceride levels, and
achieved an accuracy of 0.84 in detecting fatty liver.
46 The
FLI has since been utilised by several groups in population
studies of NAFLD.
47–49 Ultrasound (USS) is a commonly
used test in patients with suspected NAFLD, with steatosis
typically appearing as a hyperechogenic liver. A recent
study examined the accuracy of USS in 235 patients with
suspected liver disease who underwent liver biopsy, and
showed a sensitivity of 64% and speciﬁcity of 97%, rising
to 91% and 93% respectively in patients with at least 30%
steatosis.
50 However, the presence of morbid obesity con-
siderably reduces sensitivity and speciﬁcity.
51 USS is
unable to quantify the amount of fat present or provide
any staging of disease,
52 and is operator-dependent with
signiﬁcant intra- and inter-observer variability.
53
STAGING OF NAFLD
Having made a diagnosis of NAFLD, the next step is to
determine the severity, as that provides important infor-
mation on prognosis. Historically this has required liver
biopsy, although there have been many recent advances
which allow non-invasive management for many
patients. When staging patients with NAFLD, there are
two aspects to consider; (i) the level of ﬁbrosis and (ii)
the level of inﬂammation⁄ballooning (Table 1).
The histological spectrum of NAFLD ranges from
simple steatosis through steatohepatitis to ﬁbrosis and
cirrhosis. There are no pathological changes which can
deﬁnitively distinguish NAFLD from alcoholic liver dis-
ease (ALD), thus an accurate alcohol history is essential
to distinguish between these two common conditions.
54
The histological changes in NAFLD are mainly paren-
chymal and in a perivenular location, although portal
and periportal lesions may occur.
54 Simple steatosis is
usually macrovesicular resulting from accumulation of
triglycerides within hepatocytes.
44 Features of steatohepa-
titis include hepatocellular injury, characterised by bal-
looned hepatocytes, with inﬂammation and ﬁbrosis.
54
Mitochondrial abnormalities may occur in NASH, but
rarely in simple steatosis,
11 supporting a role for mito-
chondrial defects in the pathogenesis of NAFLD-related
liver injury.
54, 55 The typical histological features of stea-
tosis and inﬂammation often disappear in advanced dis-
ease,
56, 57 thus many cases of ‘cryptogenic’ cirrhosis are
likely caused by NASH.
56–58 Hepatocellular carcinoma is
a well-recognised complication of NASH-related cirrho-
sis,
59, 60 but can also be associated with precirrhotic NA-
FLD.
61, 62 Several systems have been proposed for the
histological assessment of NAFLD, of which the Kleiner
NAFLD activity score (NAS)
63 is probably the most well
established. The NAS provides a composite score based
on the degree of steatosis (0–3), lobular inﬂammation
(0–3) and hepatocyte ballooning (0–2), with an addi-
tional score for ﬁbrosis. A score of ‡5 suggests probable
or deﬁnite NASH, and <3 indicates that NASH is unli-
kely.
63 However, although liver biopsy currently remains
Table 1 | Methods for assessing ﬁbrosis and NASH.
Least invasive Fibrosis NASH
Fibroscan
NAFLD Fibrosis store⁄BARD
Fibrotest⁄ELF score
CK18 NASHTest⁄
FibroMax
Contrast USS
Most invasive Liver biopsy Liver biopsy
.
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this technique include intra-observer variation
63, 64 and
sampling variability,
65, 66 with features such as ﬁbrosis
often not uniformly distributed.
54
Non-invasive assessments of NAFLD severity
Such assessments can provide information on the
amount of liver ﬁbrosis and⁄or the presence of NASH,
features which are usually, but not always, found
together. The focus on ﬁbrosis is based on cohort studies
which demonstrate that ﬁbrosis, rather than inﬂamma-
tion, predicts outcome. Several non-invasive diagnostic
panels and scoring systems have been developed with
varying diagnostic utility. The uneven distribution of
ﬁbrosis throughout the liver in NAFLD indicates that
such scoring systems may potentially represent a more
accurate reﬂection of global liver ﬁbrosis severity than is
permitted by the current gold standard liver biopsy,
67
which samples only 1⁄50 000th of the organ and is
prone to signiﬁcant sampling error.
65, 66
Assessment of ﬁbrosis. (i) Demographic factors and
simple blood tests: Several diagnostic panels have been
developed to facilitate the non-invasive assessment of
NAFLD and differentiation between different stages of
disease. These are generally based on a number of labo-
ratory measurements, often in combination with clinical
parameters such as age, sex and BMI. Such scoring
systems have generally demonstrated greater utility in
the detection of advanced ﬁbrosis than intermediate and
early stages of ﬁbrosis, a group potentially more likely to
beneﬁt from therapeutic interventions.
37
The BARD score is a simple scoring system designed
to identify NAFLD patients with a low risk of advanced
disease. It combines three variables of BMI, AST⁄ALT
ratio (AAR) and the presence of diabetes into a weighted
sum (BMI ‡28 = 1 point, AAR of ‡0.8 = 2 points,
DM = 1 point), to generate a score from 0 to 4. In the
original study, a score of 2–4 was shown to be associated
with an odds ratio for advanced ﬁbrosis of 17 and a neg-
ative predictive value of 96%.
68 A further study of the
BARD score in 138 patients with biopsy-proven NAFLD
revealed an area under the receiver operating curve (AU-
ROC) of 0.67 (95% CI, 0.56–0.77), with sensitivity, speci-
ﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) of 51%, 77%, 45% and 81%
respectively.
69 In a recent study including 145 patients
with biopsy-proven NAFLD, McPherson et al. compared
the diagnostic performance of ﬁve simple non-invasive
tests [BARD score, NAFLD ﬁbrosis score, FIB-4 score,
AST to platelet ratio index (APRI) and ALT⁄AST ratio],
for the identiﬁcation of NASH-related advanced ﬁbrosis.
Here the BARD score demonstrated an AUROC of 0.77,
with sensitivity 89%, speciﬁcity 44%, NPV 95% and PPV
25%.
70 The BARD score was also validated in a Polish
NAFLD cohort, where an NPV of 97% was demon-
strated,
71 but appeared less useful in a Japanese cohort,
where the AUROC was 0.73 with NPV 77%.
72 The
BARD score is easily calculated and thus represents a
simple tool for excluding the presence of advanced ﬁbro-
sis in NAFLD patients.
The AST-to-platelet ratio index (APRI),
73 AST⁄ALT
ratio,
74 and FIB-4 score
75 have previously demonstrated
utility in the non-invasive assessment of ﬁbrosis in a
number of chronic liver diseases. Several recent studies
have also examined the role of these markers in NAFLD,
as will be described.
The APRI was originally developed for use in chronic
hepatitis C,
73 but its utility in NAFLD has since been
studied by a number of groups. Using this score, Cales
et al. demonstrated an AUROC of 0.866 for signiﬁcant
ﬁbrosis, 0.861 for severe ﬁbrosis and 0.842 for cirrhosis
in a study of 235 NAFLD subjects.
76 However, signiﬁ-
cantly lower values were obtained in other studies, where
AUROCs of 0.564 for signiﬁcant ﬁbrosis, 0.568 for
advanced ﬁbrosis,
77 and 0.786 for predicting cirrhosis
78
were demonstrated. In their study of 145 NAFLD
patients, McPherson et al. reported an AUROC of 0.67
for the diagnosis of advanced ﬁbrosis.
70
The AST⁄ALT ratio (AAR) is calculated using two
widely available laboratory liver function tests. In addi-
tion to its utility as an individual marker, the AAR is
also a component of several other ﬁbrosis scoring sys-
tems including the NAFLD Fibrosis score and BARD
score. Despite its simplicity, using a cut-off of 0.8 McPh-
erson et al. demonstrated an AUROC of 0.83, with sensi-
tivity 74%, speciﬁcity 78% and NPV of 93% for the
diagnosis of advanced ﬁbrosis in NAFLD using the
AAR.
70 The United States Nonalcoholic Steatohepatitis
Clinical Research Network (NASH CRN) recently inves-
tigated the utility of readily available clinical and labora-
tory variables to predict histological severity of NASH in
>600 patients with biopsy-proven NAFLD. In this study,
a combination of serum AST, ALT and the AAR per-
formed only modestly (AUROC 0.59) for predicting stea-
tosis, but was able to predict cirrhosis with an AUROC
of 0.81. However, the addition of demographic data,
comorbidities and several other routinely measured labo-
ratory tests increased the AUROCs to 0.79 for NASH
and 0.96 for cirrhosis.
79
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chemical values (platelets, ALT and AST) to assess ﬁbro-
sis. In NAFLD FIB-4 has demonstrated similar results to
the AST⁄ALT ratio where, using a cut-off of 1.3, an AU-
ROC of 0.86, sensitivity 85%, speciﬁcity 65% and NPV
of 95% were demonstrated for the diagnosis of advanced
ﬁbrosis.
70 In a US-based comparison of several non-inva-
sive markers of ﬁbrosis in 541 NAFLD patients, FIB-4
had the highest AUROC of 0.802, with PPV and NPV of
80% and 90% respectively for diagnosis of advanced
ﬁbrosis. In this study, AUROCs for the NAFLD ﬁbrosis
score, AAR, APRI, AST:platelet ratio and BARD score
were 0.768, 0.742, 0.73, 0.72 and 0.70 respectively.
80
Increased serum GGT level has also been shown to be
associated with advanced ﬁbrosis in NAFLD, with a study
of 50 NAFLD patients demonstrating an AUROC of 0.74
for the prediction of advanced ﬁbrosis. Using a cut-off
serum GGT value of 96.5 U⁄L, GGT predicted advanced
ﬁbrosis with 83% sensitivity and 69% speciﬁcity.
81
FibroMeter is a panel of serum markers which was
originally developed for staging ﬁbrosis in chronic
HCV.
82 However, FibroMeter NAFLD has since been
developed which has shown good diagnostic accuracy in
staging NASH-related ﬁbrosis. This panel combines
seven variables (age, weight, fasting glucose, AST, ALT,
ferritin and platelet count), and in a study of 235
NAFLD patients demonstrated AUROCs of 0.943 for
signiﬁcant ﬁbrosis, 0.937 for severe ﬁbrosis and 0.904 for
cirrhosis respectively. The sensitivity, speciﬁcity, PPV
and NPV of FibroMeter for diagnosing signiﬁcant ﬁbro-
sis were 78.5%, 95.9%, 87.9 and 92.1%.
76
The NAFLD ﬁbrosis score (NFS) is a panel compris-
ing six variables of age, hyperglycaemia, BMI, platelet
count, albumin and AST⁄ALT ratio, which was con-
structed using a large panel of 733 biopsy-proven NA-
FLD patients across several centres worldwide. Two cut-
off scores were generated to predict the likelihood of the
presence or absence of advanced ﬁbrosis respectively.
67
In the original study, by applying the low cut-off score
()1.455), the NFS had an NPV of 93% and 88% in the
estimation and validation groups respectively for exclud-
ing the presence of advanced ﬁbrosis. By applying the
high cut-off score (0.676), PPVs of 90% and 82% in the
estimation and validation groups respectively were
achieved for predicting the presence of advanced ﬁbrosis.
The AUROC was 0.84, and application of this model to
the study population would have avoided liver biopsy in
75% of patients, with a correct prediction in 90%.
67 In
the recent study by McPherson et al., the NFS demon-
strated an AUROC of 0.81 with NPV 92% and PPV
72%, which was the highest PPV of the four tests exam-
ined.
70 Cales et al. demonstrated an AUROC of 0.884 for
signiﬁcant ﬁbrosis, 0.932 for severe ﬁbrosis and 0.902 for
cirrhosis.
76 Studies in East Asian populations have also
demonstrated good accuracy for excluding advanced
ﬁbrosis, with NPVs of 89% and 91% demonstrated in
Japanese
72 and Chinese
83 NAFLD cohorts respectively.
The NFS also demonstrated excellent accuracy at exclud-
ing ﬁbrosis in morbidly obese subjects with NAFLD
undergoing bariatric surgery, where NPVs of 98%, 87%
and 88% for excluding advanced, signiﬁcant and any
ﬁbrosis respectively were demonstrated.
84 In a recent
meta-analyses, NFS achieved pooled AUROC, sensitivity
and speciﬁcity of 0.85 (0.80–0.93), 0.90 (0.82–0.99) and
0.97 (0.94–0.99) for the identiﬁcation of NASH with
advanced ﬁbrosis.
85 The NAFLD ﬁbrosis score thus facil-
itates the identiﬁcation of NAFLD patients with more
advanced disease who require ongoing follow-up, and
considerably reduces the requirement for liver biopsy in
the minority of patients with an indeterminate score.
70
Of these various algorithms FIB-4 and the NAFLD
ﬁbrosis score (NFS) have been validated most widely
with demonstrably superior test characteristics.
70, 85
(ii) Fibrosis biomarkers: The Original ELF (European
Liver Fibrosis) test is a panel of automated immunoas-
says to detect three markers of matrix turnover in serum:
hyaluronic acid (HA), tissue inhibitor of metalloprotein-
ase 1 (TIMP1) and aminoterminal peptide of pro-colla-
gen III (P3NP), used in combination with age.
86 The
simpliﬁed ELF panel excludes age but has a similar
diagnostic performance. The addition of ﬁve simple
markers – BMI, presence of diabetes⁄impaired fasting
glucose, AST⁄ALT ratio, platelets and albumin – to the
ELF test improved diagnostic accuracy further, with
AUROCs of 0.98, 0.93 and 0.84 for the diagnosis of
severe, moderate and no ﬁbrosis respectively.
87 The ELF
panel may also represent a useful prognostic tool, with a
one unit change in ELF score shown to be associated
with a doubling of the odds of signiﬁcant liver-related
mortality or morbidity at 6 year follow-up.
88
FibroTest is another validated marker for the quanti-
tative assessment of ﬁbrosis in NAFLD, ALD and
chronic viral hepatitis.
89 Combining ﬁve biochemical
markers of haptoglobin, a2-macroglobulin, apolipopro-
tein A1, total bilirubin and GGT, corrected for age and
gender, a mean standardised AUROC of 0.84 for
advanced ﬁbrosis in NAFLD patients was demonstrated
using FibroTest in one meta-analyses. Importantly the
diagnostic value was found to be similar for the diagno-
sis of both intermediate and extreme ﬁbrosis stages, with
J J. . K K. . D Do ow wm ma an n e et t a al l. .
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intermediate adjacent stages F2 vs. F1 to that of the
extreme stages F3 vs. F4 or F1 vs. F0.
89 FibroTest can also
be combined with two other panels – SteatoTest and
NASHTest – to form the FibroMax panel (BioPredictive,
Paris, France), which provides a simultaneous and
complete estimation of the liver injury in NAFLD.
89
FibroTest⁄FibroMax have now been widely adopted as a
non-invasive alternative to liver biopsy.
90
Other potential ﬁbrosis biomarkers include type VI col-
lagen 7S domain and hyaluronic acid (HA), with the latter
also representing a constituent of the ELF test. In a cohort
of 112 NAFLD subjects, these two biomarkers were able to
exclude advanced ﬁbrosis with AUROCs of 0.82 and 0.80,
and NPVs of 84 and 78% respectively. These biomarkers
also demonstrated PPVs of 86% and 92% and AUROCs of
0.83 and 0.80 for discriminating NASH from simple fatty
liver.
91 In a separate cohort of 72 patients, the AUROC
curves for type IV collagen 7S domain and HA were 0.767
and 0.754 respectively for the detection of advanced ﬁbro-
sis in NASH. However, after multiple regression analysis
only type IV collagen 7S domain was independently asso-
ciated with advanced ﬁbrosis in this study.
92 Other studies
of HA in NAFLD using varying cut-off levels have demon-
strated AUROCs of between 0.89 and 0.97 for detecting
advanced ﬁbrosis.
93–95 Kaneda et al. demonstrated HA to
have an AUROC, NPV, sensitivity and speciﬁcity of 0.97,
100%, 100% and 89% respectively for detecting severe
ﬁbrosis, with a lower AUROC of 0.87 demonstrated for
type IV collagen. In this study, the platelet count alone
was an independent predictor of cirrhosis, with an
AUROC of 0.98, and sensitivity, speciﬁcity, PPV and NPV
of 100%, 95%, 76% and 100% respectively using a cut-off
value of 16 · 10
4⁄lL.
94 Lesmana et al. also demonstrated
the utility of levels of HA and type IV collagen to differen-
tiate between mild (F1-2) and advanced ﬁbrosis (F3-4),
96
and in a separate study of 80 NAFLD patients the combi-
nation of HA with AST, AAR, age, gender and BMI
demonstrated an AUROC of 0.763 for distinguishing
simple steatosis and NASH.
97
In a small study of serum extracellular matrix compo-
nents in 30 NAFLD patients, serum laminin >282 ng⁄mL
was shown to have an accuracy of 87%, sensitivity 82%,
speciﬁcity 89%, PPV 82% and NPV 89% for identifying
the presence of NASH with ﬁbrosis. When combined
with type IV collagen, both speciﬁcity and PPV increased
to 100%, but with lower sensitivity and NPV of 64% and
83% respectively.
98
(iii) Radiological assessment: Although many imaging
modalities have been evaluated in NAFLD, their major
focus has been quantiﬁcation of hepatic fat, with few
allowing a reliable distinction between simple steatosis
and steatohepatitis or ﬁbrosis.
52, 99 Conventional imag-
ing techniques include ultrasound (US), computed
tomography (CT) and magnetic resonance imaging
(MRI).
Fibroscan. Transient elastography (Fibroscan, Echosens,
Paris, France) is a non-invasive method of assessing liver
ﬁbrosis which can be performed at the bedside or in the
out-patient clinic. It employs ultrasound-based technol-
ogy to measure liver stiffness (LSM), and has been vali-
dated for use in chronic hepatitis C, HIV⁄HCV
coinfection and cholestatic liver diseases.
100 Failure to
obtain a reading occurs in only 5% of cases, but is more
common in obese patients which has so far limited its
use in the NAFLD cohort,
100 although a recently intro-
duced XL probe may reduce this problem.
101 Although
Fibroscan is less well validated in NAFLD, a stepwise
increase in liver stiffness with increasing histological
ﬁbrosis was demonstrated in a study of 97 Japanese
NAFLD patients, where AUROCs for the diagnosis of sig-
niﬁcant ﬁbrosis, severe ﬁbrosis and cirrhosis were 0.88,
0.91 and 0.99 respectively.
102 A larger study including
246 NAFLD patients from two ethnic groups demon-
strated AUROCs for the diagnosis of moderate ﬁbrosis
(‡F2), bridging ﬁbrosis (‡F3) or cirrhosis (F4) of 0.84,
0.93 and 0.95 respectively.
103 In this study, the best LSM
cut-off scores for predicting F ‡ 2, F ‡ 3 and F4 were
7.0 kPa, 8.7 kPa and 10.3 kPa respectively. Cut-off values
of 5.8 kPa and 9 kPa, and 7.9 kPa and 9.6 kPa had >90%
sensitivity and speciﬁcity to rule out and rule in F2 and
F3 ﬁbrosis respectively. The cut-off of 10.3 kPa for F4
disease had 92% sensitivity and 88% speciﬁcity.
103 In this
study, if liver biopsy was reserved for those patients with
LSM of ‡8.7 kPa, 32% would require the procedure,
which would miss only 4.8% patients with F3 and 0.6%
patients with cirrhosis. However, if biopsy was performed
only in those with scores between 7.9 and 9.6 kPa, only
16% patients would require biopsy.
103 In a 2010 meta-
analyses of non-invasive assessment tools in NAFLD,
transient elastography demonstrated pooled AUROC,
sensitivity and speciﬁcity of 0.94 (0.90–0.99), 0.94 (0.88–
0.99) and 0.95 (0.89–0.99).
85 Although further studies will
undoubtedly add to the current evidence base, Fibroscan
has now been validated in NAFLD,
104 and represents a
useful tool for rapid, non-invasive assessment of liver
ﬁbrosis and determining need for biopsy.
An MR equivalent of transient elastography has
recently demonstrated excellent diagnostic accuracy with
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for detecting all grades of ﬁbrosis.
105 MR elastography
was also associated with a higher technical success rate
than US elastography,
106 and hepatic stiffness did not
appear to be affected by steatosis using this tech-
nique
105 which had been a previous concern.
107 How-
ever, this technique remains experimental at the present
time.
The combination of transient elastography with one
or more of the serum marker panels described above
represents a potential approach to the non-invasive mea-
surement of ﬁbrosis in NAFLD.
37
Assessment of NASH inﬂammation and steatosis. (i)
Serum markers: SteatoTest combines 10 readily available
blood tests with age, gender and BMI, and in a study of
>2000 patients with viral hepatitis, NAFLD or ALD, dem-
onstrated an AUROC of 0.8 for the diagnosis of steatosis,
which was superior to that of GGT, ALT or ultra-
sound.
90, 108 NASHTest combines 13 biochemical and
clinical variables to predict the presence or absence of
NASH, achieving speciﬁcity, sensitivity, PPV and NPV of
94%, 33%, 66% and 81% respectively.
109 Together with
FibroTest, these three panels comprise the FibroMax panel
described previously.
89
Many other potential serum biomarkers have been
identiﬁed which are typically markers of the key mech-
anisms believed to be involved in NASH pathogenesis,
such as inﬂammation, oxidative stress, apoptosis and
insulin resistance.
44 Inﬂammation is associated with an
increase in tumour necrosis factor-alpha (TNF-a) and
decreased adiponectin expression (measured by ELISA)
and this cytokine imbalance does appear to correlate
with NASH,
110–112 although the accuracy or clinical
usefulness of these markers is yet to be determined.
113
Shimada et al. observed the serum adiponectin level to
be signiﬁcantly lower in patients with early-stage
NASH (3.6 lg⁄mL) than in those with simple steatosis
(6.0 lg⁄mL), with an AUROC of 0.765, sensitivity 68%
and sensitivity 79% for distinguishing early-stage
NASH. In this study, the combination of serum adipo-
nectin level with HOMA-IR and type IV collagen 7S
demonstrated a sensitivity of 94% and speciﬁcity of
74% for diagnosing NASH.
114 Hui et al. also reported
signiﬁcantly lower adiponectin levels and higher
HOMA-IR in patients with NASH compared with sub-
jects with simple steatosis, and demonstrated an AU-
ROC of 0.79 for the combination of these markers for
distinguishing between steatohepatitis and steatosis.
115
However, the relationship between adiponectin levels
and severity of hepatic ﬁbrosis remains to be estab-
lished.
116, 117
The inﬂammatory marker C-reactive protein (CRP),
measured using immunometric assay, has demonstrated
mixed results in NASH. While some studies have
shown a signiﬁcant increase in high-sensitivity CRP lev-
els in NASH patients compared with controls,
118, 119
another study demonstrated no signiﬁcant difference.
120
CRP also lacks speciﬁcity for hepatic inﬂammation.
Interleukin-6 (IL-6) is another marker of inﬂammation
which has been shown to be elevated in NASH.
121 In a
study comparing 43 NASH patients, 40 subjects with
steatosis and 48 controls, normal levels of IL-6 were
highly speciﬁc in conﬁrming the absence of NASH,
with an AUROC of 0.817 for distinguishing NASH
from simple steatosis. The same study also demon-
strated signiﬁcantly elevated levels of vascular endothe-
lial growth factor (VEGF) concentrations in NASH,
although the AUROC of 0.678 was lower than for IL-
6.
122 IL-6 levels were also independently associated with
ﬁbrosis in a study by Lemoine et al., where the combi-
nation of HOMA-IR with the adiponectin⁄leptin ratio
demonstrated an AUROC of 0.82 for distinguishing
between NASH and simple steatosis.
123
Indicators of oxidative stress, including lipid peroxida-
tion products (measured using a spectroﬂuorometric
method), vitamin E levels (measured using reverse phase
high performance liquid chromatography), and copper-
to-zinc superoxide dismutase and glutathione peroxidase
(GSH-Px) activity (measured using commercial antioxi-
dant assay kits), have been investigated as surrogate
markers of NASH. However, most studies to date have
been small with mixed results,
113, 124, 125 and it is not
yet clear whether or not oxidative stress in the liver is
accurately reﬂected in the serum.
126
Thioredoxin (TRX) is stress-inducible thiol-containing
protein which may represent a clinically useful indicator
of oxidative stress.
127 In a small study of 57 patients, Su-
mida et al. demonstrated signiﬁcantly elevated serum
TRX levels in patients with NASH compared with those
with simple steatosis and healthy controls, with an AU-
ROC of 0.785 for distinguishing NASH from simple stea-
tosis.
127 Similar ﬁndings have been reported elsewhere,
with a correlation between serum TRX and ferritin levels
also observed.
128
Apoptosis plays an important role in the liver injury
observed in NAFLD,
129 and cytokeratin-18 (CK-18) rep-
resents a useful marker of this process. In a US multi-
centre validation study including 139 NAFLD patients
and 150 controls, Feldstein et al. demonstrated that
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ª 2010 Blackwell Publishing LtdTable 2 | Non-invasive techniques for diagnosis of (a) NASH and (b) ﬁbrosis in patients with NAFLD in descending
order of diagnostic accuracy
a)
Diagnostic technique Size of cohort used in studies⁄Comments Popularity
Contrast-enhanced
ultrasound
Study including 64 patients with normal liver, NAFLD or NASH,
demonstrated AUROC of 100% for diagnosis of NASH
145
Use currently limited to clinical
trials
NASHTest Study of 257 patients: 160 in training group and 97 in validation
group. Speciﬁcity, sensitivity, PPV and NPV of 94%, 33%, 66% and
81% for diagnosis of NASH. Can be combined with SteatoTest and
FibroTest in Fibromax
109
Use mainly conﬁned to
specialist liver centres
CK-18 Multi-centre validation study including 139 NAFLD patients
demonstrated AUROC of 0.83 for NASH diagnosis.
130
Recently received independent validation for diagnosing
NASH in meta-analyses demonstrating pooled AUROC,
sensitivity and speciﬁcity for NASH of 0.82, 0.78 and 0.87
85
Use currently limited to clinical
trials but holds promise for
more widespread application
b)
Diagnostic technique Size of cohort used in studies⁄Comments Popularity
ELF test + simple
markers
Validation study included 196 NAFLD patients. AUROCs of 0.84,
0.93 and 0.98 for detecting no ﬁbrosis, moderate ﬁbrosis and
severe ﬁbrosis respectively
87
Use mainly conﬁned to
specialist liver centres
FibroMeter Study of 235 NAFLD patients demonstrated AUROCs of 0.943 for
signiﬁcant ﬁbrosis, 0.937 for severe ﬁbrosis and 0.904 for cirrhosis
respectively. Sensitivity, speciﬁcity, PPV, NPV for diagnosis of
signiﬁcant ﬁbrosis were 79%, 96%, 88% and 92%
76
Use mainly conﬁned to
specialist liver centres
Fibroscan Largest study included 246 NAFLD patients, with AUROCs of 0.84,
0.93 and 0.95 for diagnosis of ‡F2, ‡F3 and ‡F4 ﬁbrosis
respectively.
103 Meta-analyses of non-invasive assessment tools in
NAFLD demonstrated pooled AUROC, sensitivity and speciﬁcity of
0.94, 0.94 and 0.95
85
Use mainly conﬁned to
specialist liver centres.
Equipment expensive
NAFLD Fibrosis
Score (NFS)
Validation study included 733 patients with biopsy-proven NAFLD:
480 in estimation group and 253 in validation group. PPVs of 90%
and 82% for predicting advanced ﬁbrosis and NPVs of 93% and
88% for excluding advanced ﬁbrosis in estimation and validation
groups respectively, with AUROC 0.84
67
For diagnosis of advanced ﬁbrosis, AUROC of 0.768 demonstrated in
study of 541 patients,
80 and AUROC of 0.81 in study of 145 NAFLD
patients.
70 In study of 235 patients, AUROCs of 0.884 for
signiﬁcant ﬁbrosis, 0.932 for severe ﬁbrosis, and 0.902 for
cirrhosis
76
Similar efﬁcacy demonstrated in East Asian
72, 83 and morbidly obese
cohorts
84
Widely used in secondary care
clinical practice. Accessibility
increased by availability of
on-line calculator. Use
advocated in recent review of
non-invasive scoring systems
for exclusion of advanced
ﬁbrosis
70
FibroTest Meta-analyses including 267 NAFLD patients demonstrated mean
AUROC of 0.84 for detecting advanced ﬁbrosis. Can be combined
with SteatoTest and NASHTest in Fibromax
89
Use mainly conﬁned to
specialist liver centres
FIB-4 Study of 541 NAFLD patients demonstrated AUROC of 0.802, with
PPV 80% and NPV 90% for diagnosis of advanced ﬁbrosis.
80 Study
of 145 NAFLD patients demonstrated AUROC of 0.86, sensitivity
85%, speciﬁcity 65% and NPV of 95%
70
Use advocated in recent review
of non-invasive scoring
systems for exclusion
of advanced ﬁbrosis
70
APRI (AST-to-platelet
ratio index)
Study of 235 NAFLD patients demonstrated AUROCs of 0.866 for
signiﬁcant ﬁbrosis, 0.861 for severe ﬁbrosis and 0.842 for
cirrhosis.
76 AUROCs of 0.73 for advanced ﬁbrosis in study of 541
NAFLD patients,
80 and 0.67 in study of 145 patients
70
Developed for use in HCV.
Not speciﬁc for NAFLD
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cantly higher in patients with biopsy-proven NASH than
in those with a borderline diagnosis and normal controls,
with an AUROC of 0.83 for NASH diagnosis. CK-18
was an independent predictor of both NASH and sever-
ity of disease.
130 Other studies have corroborated these
ﬁndings,
131–137 suggesting that CK-18 represents a poten-
tially useful biomarker for the diagnosis and differentia-
tion of NASH from simple steatosis. CK-18 recently
received independent validation for diagnosing NASH in
a 2010 meta-analyses, where pooled AUROC, sensitivity
and speciﬁcity for NASH were 0.82 (0.78–0.88), 0.78
(0.64–0.92), and 0.87 (0.77–0.98) respectively.
85 An AU-
ROC of 0.88 for diagnosis of NASH was also demon-
strated in a morbidly obese population where, in
addition, CK-18 levels were observed to fall signiﬁcantly
following bariatric surgery.
138 Younossi et al. evaluated
the diagnostic utility of several ELISA-based assays in
patients with biopsy-proven NASH. This study found
that the levels of cleaved CK-18 (M30 antigen), and
intact CK-18 (M65) predicted histological NASH with
70% sensitivity, 84% speciﬁcity, AUROC 0.711 and 64%
sensitivity, 89% speciﬁcity and AUROC 0.814 respec-
tively. Histological NASH was found to be predicted by
a combination of four ELISA-based tests – cleaved CK-
18, a product of the subtraction of cleaved CK-18 level
from intact CK-18 level, serum adiponectin and serum
resistin – with a sensitivity 96%, speciﬁcity of 70% and
AUROC of 0.91.
139 CK18 fragment has also been com-
bined with ALT levels and the presence of the metabolic
syndrome in the ‘Nice model’, a composite model where
AUROCs of 0.83–0-88 were demonstrated for the diag-
nosis of NASH, as deﬁned by a NAS score ‡5, in a mor-
bidly obese population.
140
Plasma homocysteine (Hcy) levels were shown to dis-
tinguish NASH from simple steatosis with good accuracy
in a Turkish study of 71 NAFLD patients. Using a
threshold of 11.935 ng⁄mL, sensitivity and speciﬁcity
were 91.7% and 95.7% with an AUROC of 0.948 for pre-
dicting NASH.
141
Serum prolidase enzyme activity (SPEA) catalyses the
ﬁnal step of collagen breakdown by liberating free pro-
line for collagen recycling, and is reported to be of hepa-
tic origin.
142 In a Turkish study of 54 NAFLD patients,
SPEA was signiﬁcantly greater in patients with NASH
than those with simple steatosis or controls, and posi-
tively correlated with the grade of liver fatty inﬁltration,
lobular inﬂammation, stage of ﬁbrosis and NAFLD activ-
ity score.
142 In this study, the SPEA was shown to be
superior to AST, ALT or the AAR for distinguishing
NASH from simple steatosis, with an AUROC of 0.85,
and also the most useful of these tests for predicting lob-
ular inﬂammation, NAFLD activity score and ﬁbrosis.
142
Other novel biomarkers which may be of potential utility
Table 2 | (Continued)
b)
Diagnostic technique Size of cohort used in studies⁄Comments Popularity
AST⁄ALT ratio (AAR) Using cut-off of 0.8, study of 145 NAFLD patients demonstrated
AUROC of 0.83, sensitivity 74%, speciﬁcity 78% and NPV 93% for
diagnosis of advanced ﬁbrosis.
70 AUROC 0.742 for advanced
ﬁbrosis in study of 541 NAFLD patients
80
Easy to calculate. Also a
component of some other
ﬁbrosis scoring systems eg.
NFS, BARD. Use advocated in
recent review of non-invasive
scoring systems for exclusion
of advanced ﬁbrosis
70
BARD score Original study included 827 NAFLD patients with NPV 96% for
excluding advanced ﬁbrosis.
68 AUROC 0.70 for advanced ﬁbrosis in
study of 541 NAFLD patients.
80 Study of 145 patients showed
AUROC of 0.77, with sensitivity 89%, speciﬁcity 44%, NPV 95%
and PPV 25%
70
Simple to use in primary or
secondary care. Use
advocated in recent review of
non-invasive scoring systems
for exclusion of advanced
ﬁbrosis
70
Techniques to non-invasively distinguish NASH from simple steatosis remain largely experimental, although show much promise
for the future. Several methods are available for the non-invasive diagnosis⁄exclusion of ﬁbrosis in patients with NAFLD. The
BARD score is the simplest scoring system to calculate in the clinic, but the NAFLD ﬁbrosis score can also be easily calculated
by entering the relevant details into a freely available online calculator
70 (http://naﬂdscore.com). Currently FibroTest⁄FibroMax,
FibroMeter and the ELF test are each only available from a single laboratory at signiﬁcant cost, which has limited their use to
mainly specialist liver centres.
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levels
143 and tissue polypeptide speciﬁc antigen.
144 Fur-
ther study of these markers is warranted.
It should be highlighted that although some of the
non-invasive serum markers described earlier are already
widely used in the assessment and staging of NASH, fur-
Stage 1
NAFLD confirmed
Stage 2
Calculate NAFLD fibrosis score 
<–2.5 –2.5 to
–1.455
–1.455 to
0.676 >0.676
Low risk Indeterminate risk High risk
Reassure Refer/Further investigation
Repeat NFS in: Fibroscan
3–5 years 1 year <7.9 kPa 7.9–9.6 kPa
NAS Indeterminate NASH
(≥F3 fibrosis)
NAS NASH
(activity++ or ≥F2 fibrosis)
Management of NASH
and risk factors 
Discharge
back to
primary care
>9.6 kPa
Recommend
liver biopsy
Figure 2 | Proposed algorithm for the work-up of a patient with NAFLD. Patients with a NAFLD ﬁbrosis score below
the lower cut-off level have a low risk of signiﬁcant ﬁbrosis and subsequent disease progression and can be safely
managed in primary care. Referral to specialist care is indicated if disease progression is suspected on clinical or bio-
chemical grounds. A score in the indeterminate range or above merits further investigation by use of modalities such
as specialist scans or blood tests. Liver biopsy should be considered for those patients in whom non-invasive tests are
inconclusive. The use of Fibroscan in this algorithm may later be replaced by serum marker panels. NFS, NAFLD
ﬁbrosis score; NAS, non-alcoholic steatosis.
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conﬁdence in their utility (Table 2).
(ii) Radiological assessment: Contrast-enhanced ultra-
sound using Levovist is the ﬁrst imaging technique to
demonstrate efﬁcacy in distinguishing between simple
steatosis and NASH. In a study of 64 patients with either
normal liver, NAFLD or NASH, this modality was able
to diagnose NASH with an AUROC of 100%.
145 The
accumulation of Levovist microbubbles in the liver
parenchyma was shown to be decreased in NASH but
not in NAFLD or chronic viral hepatitis, with the
decrease seen in NASH correlating with ﬁbrosis rather
than steatosis. Severe decrease was seen in both NASH
and ASH livers, especially in the presence of bridging
ﬁbrosis (F3); however, the same stage of ﬁbrosis in
chronic viral hepatitis showed only a mild decrease or
normal uptake of Levovist. These differences may be
explained both by changes in Kupffer cell function and
differences between pericellular and periportal ﬁbrosis in
provoking disturbance of Levovist microbubble accumu-
lation.
145 Although this remains an experimental tech-
nique at present, evolving imaging modalities may thus
soon permit the non-invasive differentiation between
steatosis and NASH.
The diagnostic yield using CT is similar to that of US in
NAFLD. Unenhanced CT shows low attenuation of the
steatotic liver in contrast to the spleen, and the severity of
steatosis has been shown to correlate with the liver:spleen
(L⁄S) attenuation ratio.
146 AC TL⁄S cut-off of value of 0.8
yielded 100% speciﬁcity and 82% sensitivity for diagnosing
macrovesicular steatosis of 30% or greater,
147 although a
CT L⁄S cut off of 1.0 for deﬁning steatosis has been used
in some studies.
148 Accuracy of unenhanced CT is greatly
reduced with lesser degrees of steatosis.
147 Other patholo-
gies, such as hepatic siderosis, may also alter attenuation
values leading to misdiagnosis,
149, 150 and the radiation
exposure associated with CT limits its use in younger
patients and in longitudinal studies.
149
Fibroscan has also recently demonstrated utility in
detecting and quantifying steatosis, using a novel attenu-
ation parameter termed ‘Controlled Attenuation Parame-
ter’ (CAP), which was devised to speciﬁcally target the
liver using a process based on Vibration Control Tran-
sient Elastography (VCTE, Echosens, Paris, France). A
study of 115 patients using liver biopsy as reference
demonstrated that CAP was able to accurately detect
>10% (S1), >33% (S2) and >67% (S3) steatosis with AU-
ROCs of 0.91, 0.95 and 0.89 respectively. CAP evaluated
by the Fibroscan is not affected by ﬁbrosis, and advanta-
ges over other imaging techniques include its ability to
quantify and detect steatosis from only 10% of liver inﬁl-
tration, and being non-ionising, relatively cheap and
non-operator dependent.
151
There are at present no evidence-based guidelines for
the work-up⁄staging of a patient with conﬁrmed NAFLD.
Although alternative approaches may be equally effective,
a proposed algorithm for the work-up of patients with
NAFLD is detailed in Figure 2. This combination of
inexpensive non-invasive algorithms prior to more
detailed examinations should hopefully permit a cost-
effective and efﬁcient way of investigating what is likely
to be a large number of potential patients.
CONCLUSIONS
Non-alcoholic fatty liver disease now represents the most
common cause of liver disease in the Western world,
and rising levels of obesity, diabetes and the metabolic
syndrome render it an increasingly important cause of
morbidity and mortality. While simple steatosis carries a
relatively benign prognosis, a signiﬁcant proportion of
patients will progress to NASH and later cirrhosis with
risk of hepatocellular carcinoma. Although liver biopsy
remains the gold standard for disease assessment, the
development of risk scores, biomarker panels and ultra-
sound modalities has resulted in much improved identiﬁ-
cation of at risk patients without recourse to use of liver
biopsy on a routine basis.
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